SGMT vs. VTGN, SYRS, RLMD, ELYM, RZLT, COYA, NVCT, AMLX, INCR, and CTMX
Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Vistagen Therapeutics (VTGN), Syros Pharmaceuticals (SYRS), Relmada Therapeutics (RLMD), Eliem Therapeutics (ELYM), Rezolute (RZLT), Coya Therapeutics (COYA), Nuvectis Pharma (NVCT), Amylyx Pharmaceuticals (AMLX), InterCure (INCR), and CytomX Therapeutics (CTMX). These companies are all part of the "pharmaceutical preparations" industry.
Sagimet Biosciences (NASDAQ:SGMT) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.
87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are held by institutional investors. 1.0% of Vistagen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Vistagen Therapeutics received 270 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 72.24% of users gave Vistagen Therapeutics an outperform vote.
Sagimet Biosciences has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,073.51%. Sagimet Biosciences' return on equity of 0.00% beat Vistagen Therapeutics' return on equity.
In the previous week, Vistagen Therapeutics had 2 more articles in the media than Sagimet Biosciences. MarketBeat recorded 4 mentions for Vistagen Therapeutics and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.67 beat Vistagen Therapeutics' score of 0.28 indicating that Sagimet Biosciences is being referred to more favorably in the media.
Sagimet Biosciences currently has a consensus target price of $41.50, indicating a potential upside of 922.17%. Vistagen Therapeutics has a consensus target price of $19.00, indicating a potential upside of 300.00%. Given Sagimet Biosciences' higher possible upside, research analysts clearly believe Sagimet Biosciences is more favorable than Vistagen Therapeutics.
Sagimet Biosciences has higher revenue and earnings than Vistagen Therapeutics.
Summary
Sagimet Biosciences beats Vistagen Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Sagimet Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sagimet Biosciences Competitors List
Related Companies and Tools
